ESMO Asia 2024：和誉医药以口头报告形式展示其口服PD-L1抑制剂ABSK043的最新1期研究结果

和誉医药在本届ESMO Asia 2024 大会上展示信息如下：

报告编号：485

标题：用于治疗晚期实体瘤患者的口服PD-L1抑制剂ABSK043的1期研究最新结果

报告时间：12月6日 10:42AM-10:52 AM

关于ABSK043

ABSK043是和誉医药独立自主研发并拥有全球知识产权的一款全新的具备优异活性及高度选择性的口服小分子PD-L1抑制剂。肿瘤细胞可以利用PD-1及其配体PD-L1这些免疫检查点来逃避免疫监管和清除，抑制或限制T细胞应答。ABSK043可与PD-L1受体特异性结合并诱导其从细胞表面内吞，有效地抑制PD-1/PD-L1的相互作用，解除PD-L1介导的T细胞活化抑制作用。ABSK043在多个临床前模型中展现出与已获批PD-L1抗体相当的抗肿瘤功效。截止目前，全球已有多款PD-1/PD-L1抗体药物获批上市，但并无PD-1/PD-L1小分子药物获批。ABSK043目前正在澳大利亚和中国开展针对晚期实体肿瘤的I期临床试验。

ESMO Asia 2024: Oral presentation by Abbisko Therapeutics on updated results from a phase 1 study of ABSK043, an oral PD-L1 inhibitor

On December 6, 2024, Abbisko Therapeutics Co., Ltd. (HKEX: 02256) announced that it has delivered an oral presentation of updated phase 1 study results on its independently discovered oral PD-L1 inhibitor, ABSK043, in patients with advanced solid tumors at European Society For Medical Oncology Asia Congress 2024 （“ESMO Asia 2024”）in Singapore.

The results of the study show that at 600mg -1000mg BID, ABSK043 demonstrated a favorable safety profile and impressive anti-tumor activity as a single agent. More prominent efficacy was observed in non-small cell lung cancer （“NSCLC”） patients with high PD-L1 expression, even with EGFR or KRAS mutations and received prior systemic therapies. These findings support a continuing investigation of ABSK043, in EGFR-mutated lung cancers and various other solid tumors.

Abbisko presentation at ESMO Asia 2024:

Presentation Number: 485

Title: Updated Results of Oral PD-L1 Inhibitor ABSK043 in Advanced Solid Tumor Patients (pts) from a Phase 1 Study

Time: December 6, 10:42AM-10:52 AM

About ABSK043

ABSK043 is a novel, orally administered small molecule PD-L1 inhibitor displaying exceptional activity and high selectivity independently discovered and wholly owned by Abbisko Therapeutics. Tumor cells can exploit immune checkpoints such as PD-1 and its ligand PD-L1 to evade immune detection and clearance, thereby suppressing or restricting T-cell responses. ABSK043 selectively binds to the PD-L1 receptor and induces its internalization from the cell surface, effectively inhibiting the PD-1/PD-L1 interaction and alleviating PD-L1-mediated suppression of T-cell activation. In preclinical models, ABSK043 has demonstrated anti-tumor efficacy comparable to approved PD-L1 antibodies. While several PD-1/PD-L1 monoclonal antibodies have been approved worldwide, there are currently no approved orally available PD-1/PD-L1 small molecule drugs. ABSK043 is currently being studied in an ongoing Phase I clinical trial for advanced solid tumors in Australia and China.